These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35223121)

  • 1. Ciprofloxacin-Resistant
    Panholzer J; Neuboeck M; Shao G; Heldt S; Winkler M; Greiner P; Fritsch N; Lamprecht B; Salzer H
    Case Rep Pulmonol; 2022; 2022():1008330. PubMed ID: 35223121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
    Millar BC; McCaughan J; Rendall JC; Moore JE
    Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
    Dundar D; Otkun M
    Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant
    Craddock VD; Steere EL; Harman H; Britt NS
    Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community-acquired, hospital-acquired, and healthcare-associated pneumonia caused by Pseudomonas aeruginosa.
    Fujii A; Seki M; Higashiguchi M; Tachibana I; Kumanogoh A; Tomono K
    Respir Med Case Rep; 2014; 12():30-3. PubMed ID: 26029534
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G; Zarakolu P; Hasçelik G; Akova M
    Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delafloxacin as a treatment option for community-acquired pneumonia infection.
    Nascimento-Carvalho CM
    Expert Opin Pharmacother; 2021 Oct; 22(15):1975-1982. PubMed ID: 34346823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'TAVR Infected Pseudomonas Endocarditis': a case report.
    Essien F; Patterson S; Estrada F; Wall T; Madden J; McGarvey M
    Ther Adv Infect Dis; 2022; 9():20499361221138459. PubMed ID: 36465429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem-resistant Pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review.
    He L; He A; Qian Y
    Ann Palliat Med; 2021 Jan; 10(1):810-817. PubMed ID: 33545803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
    Cho JC; Crotty MP; White BP; Worley MV
    Pharmacotherapy; 2018 Jan; 38(1):108-121. PubMed ID: 29059465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility and virulence genes of clinical and environmental isolates of
    Liew SM; Rajasekaram G; Puthucheary SA; Chua KH
    PeerJ; 2019; 7():e6217. PubMed ID: 30697478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.